LBA36 - Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab…
jwood@krftwrk.caNovember 14, 2018
ASCO 2017. LBA 3. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy…
jwood@krftwrk.caJuly 10, 2017
GICS 2017. Abstract 519: Nivolumab alone or in combination with ipilimumab in patients with DNA…
jwood@krftwrk.caFebruary 22, 2017
GICS 2017. Abstract 303: Efficacy and safety of liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin…
jwood@krftwrk.caFebruary 22, 2017
On January 13th, 2017 CARE™ faculty specialists representing the fields of gastroenterology, hematology, oncology, respirology…
jwood@krftwrk.caJanuary 23, 2017
SABCS 2016. P5-16-17. Population based long-term outcomes of pathologic complete response after neoadjuvant chemotherapy in…
jwood@krftwrk.caDecember 21, 2016
SABCS 2016. P4-22-13. Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+…
jwood@krftwrk.caDecember 21, 2016
SABCS 2016. S1-03. First results from the multicenter phase III DATA study comparing 3 versus…
jwood@krftwrk.caDecember 21, 2016
CARE™ (Community, Academic, Research, Education) develops a number of educational initiatives throughout the year, designed…
jwood@krftwrk.caNovember 18, 2016
